NFE2L2 and hepatocellular carcinoma: A previous study demonstrated that miR-340 reverses cisplatin resistance in hepatocellular carcinoma cell lines by targeting the nuclear factor (erythroid-derived 2)-like 2-dependent antioxidant pathway [43].